相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
Bruce Neal et al.
AMERICAN HEART JOURNAL (2013)
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes A 24-week, randomized, double-blind, placebo-controlled trial
Hans-Ulrich Haering et al.
DIABETES CARE (2013)
Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
J. P. H. Wilding et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2013)
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
David Polidori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Urinary tract infections in patients with diabetes treated with dapagliflozin
Kristina M. Johnsson et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Urinary tract infection in patients with diabetes mellitus
Reinhard Fuenfstueck et al.
CLINICAL NEPHROLOGY (2012)
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study
L. E. Nicolle et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
D. Devineni et al.
DIABETES OBESITY & METABOLISM (2012)
Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents
William N. Washburn
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
Incidence of urinary tract infection among patients with type 2 diabetes in the UK General Practice Research Database (GPRD)
Ishan Hirji et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2012)
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Muhammad A. Abdul-Ghani et al.
ENDOCRINE REVIEWS (2011)
Renal glucose reabsorption inhibitors to treat diabetes
Clifford J. Bailey
TRENDS IN PHARMACOLOGICAL SCIENCES (2011)
Familial Renal Glucosuria and SGLT2: From a Mendelian Trait to a Therapeutic Target
Rene Santer et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials
Niklas Hammar et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2010)
Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus
AIM Hoepelman et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2003)
分享论文
